Best Life Sciences Companies in Emeryville, United States
The 36 best Life Sciences companies in Emeryville, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: BioAge Labs.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Emeryville
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | BioAge Labs Provider of a bioinformatics platform for biomarkers and drug discovery | $294M | 31 mo ago | 43 43 → 100 (+133%) | — | — | 101 patents NLRP3 inflammasome inhibitors and apelin receptor modulators for BBB, muscle, weight therapies | — |
| 2 | Nutcracker Therapeutics Developer of mRNA therapeutics | $227M | 53 mo ago | 143 | 2018 | Igor Khandros Co-Founder & CEO | 253 patents Microfluidic and analytical platforms for nucleic acid delivery and lipid nanoparticle characterization | — |
| 3 | NovaBay Pharmaceuticals Developer of eye care and wound care products 32Funding top 21%Product top 35%News top 46%Talent bottom 49% All 10 signals ▾Fundingtop 21% Producttop 35% Newstop 46% Talentbottom 49% Moatbottom 44% Marketbottom 43% Techbottom 41% Growthbottom 40% Globalbottom 38% Fin. healthbottom 37% Funding: Raised $220M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) Product: 0 product launch events in 12 mo · Company stage: Public rank vs industry peers · Fliar Intelligence Index 32/100 | $220M | 8 mo ago | 33 33 → 38 (+15%) | 2000 | Justin Hall CEO | — | — |
| 4 | 4D Molecular Therapeutics Developer of gene therapeutics for genetic disorders | $187M | 75 mo ago | 147 147 → 216 (+47%) | 2013 | David Kirn Md Co-Founder & CEO | 246 patents AAV-based gene delivery and biologic therapeutics for pulmonary and ocular diseases | — |
| 5 | Eureka Therapeutics Biopharmaceutical firm pioneering T-cell therapies for solid tumors and malignancies | $155M | 39 mo ago | 42 42 → 48 (+14%) | 2006 | Cheng Liu Founder & CEO | 579 patents Therapeutic antibodies and constructs targeting cancer-associated antigens for oncology. | — |
| 6 | Zogenix Developing drug delivery systems for treatment of CNS diseases | $149M | 107 mo ago | 159 | 2006 | Bret Megargel Co-Founder | 150 patents Patents concentrated in health & consumer products | — |
| 7 | Berkeley Lights Developer of microfluidics-based systems for single-cell manipulation | $125M | 95 mo ago | 267 | 2011 | Ming Wu Co-Founder | 868 patents High-throughput microfluidic cell analysis and manipulation for therapeutic cell manufacturing. | — |
| 8 | RegCell Developer of cell therapies focused on restoring immune tolerance for autoimmune diseases | $117M | 18 mo ago | — | 2016 | Shimon Sakaguchi Founder | — | — |
| 9 | Adamas Pharma Developing therapeutics by enhancing the pharmacokinetic profiles of approved drugs to treat Parkinson's… | $68M | 147 mo ago | 142 | 2002 | Neil McFarlane CEO | — | — |
| 10 | Gritstone bio Developer of immunotherapies for cancers and infectious diseases | $65M | 35 mo ago | 231 | 2015 | Andrew Allen President | 275 patents Patents concentrated in chemistry & materials | — |
| 11 | Tethys BioScience Biological Markers for Diagnoses | $53M | 193 mo ago | 81 | 2002 | — | 81 patents Biomarker-based diagnostics for diabetes, osteoporosis, and metabolic disease using legacy samples | — |
| 12 | KineMed Drug development platform | $48M | 134 mo ago | 53 | 2001 | David Fineman president and ceo | 67 patents Patents concentrated in computing, sensing & instrumentation | — |
| 13 | Lucira Pfizer Manufacturer of single use molecular tests | $33M | 80 mo ago | — | 2013 | Debkishore Mitra Co-Founder | — | — |
| 14 | Habit Personalized nutrition and wellness solutions for healthy eating habits | $32M | 118 mo ago | — | 2015 | — | 7 patents Personalized nutrition and CNS disease monitoring using biometric and genetic data | — |
| 15 | Peplin Topical gel for the treatment of actinic (solar) keratosis. | $31M | 217 mo ago | — | 1999 | Tom Wiggans CEO | — | — |
| 16 | Triplebar Developer of screening systems to address medical needs | $21M | 32 mo ago | 40 | 2019 | Jeremy Agresti Founder and CTO | — | — |
| 17 | Bruker Cellular Analysis Developer of solutions for cellular analysis and functional cell biology | $17M | 75 mo ago | — | 2011 | Igor Khandros Co-Founder | 71 patents Patents concentrated in transport & manufacturing processes | — |
| 18 | Bionovo Develops botanically-derived drugs for menopausal symptoms and cancer | $16M | 193 mo ago | 51 | 2002 | Isaac Cohen Co-Founder & CEO | 198 patents Phytochemical extracts for estrogen therapy, anti‑cancer, and weight‑loss applications | — |
| 19 | Nano Precision Medical Implantable biopharmaceutical technology company improving chronic disease treatment and patient adherence | $15M | 126 mo ago | 35 | 2009 | — | — | — |
| 20 | Newomics Platform technology based on Microfluidic chip based LC-MS to enable precision medicine | $12M | 13 mo ago | 9 | 2011 | — | 15 patents Biomedical diagnostics and bio-particle sorting/separation technologies. | — |
| 21 | Vivani Developer of a drug delivery medical device for diabetes | $8M | 17 mo ago | 37 37 → 36 (-3%) | 2009 | Adam Mendelsohn Co-Founder & CEO | — | 2 launchs |
| 22 | HX Diagnostics Develops and commercializes diagnostic products for infectious diseases | $8M | 203 mo ago | — | 2006 | Wendy Benson President & CEO | 94 patents Cooperative primer nucleic acid amplification for variant genotyping and infection diagnostics | — |
| 23 | Milagen Cancer diagnostics company focused on early detection and recurrence monitoring | $7M | 75 mo ago | — | 1997 | Moncef Jendoubi Founder & CEO & President & CSO | 11 patents High‑throughput cervical cancer diagnostics using molecular biomarkers and detection devices | — |
| 24 | Crystal Biosciences Specialty company developing antibodies | $5M | 120 mo ago | 3 | 2008 | — | — | — |
| 25 | Reservoir Neuroscience Provider of therapeutics solution for dysfunctional blood vessels in the brain | $4M | 34 mo ago | 5 | 2019 | Aaron Friedman Co-Founder & CEO | 17 patents Small-molecule EP2 receptor antagonists for neurotherapeutics | — |
| 26 | ESTRELLA BIOPHARMA Developer of immunotherapies for cancer treatment | $3M | 15 mo ago | — | 2022 | Cheng Liu CEO | — | — |
| 27 | Topaz Biosciences Developer of enzyme ingredients for skin microbiome rebalancing | $3M | 13 mo ago | — | 2022 | Teresa Shock Co-Founder | — | — |
| 28 | Radiant Genomics Provider of natural product discovery and production platform | $600K | 134 mo ago | 13 | 2012 | — | — | — |
| 29 | Drift Biotechnologies Provider of bioinformatics solutions | $125K | 39 mo ago | 2 | 2020 | Evan Zimmerman Founder | — | — |
Top 12 Life Sciences companies in Emeryville
#1
Public · Emeryville, California · founded 2000 · 33 employees$219.5Mraised▾
Developer of eye care and wound care products. The company's products include Avenova An antimicrobial lid and lash solution for eye care, PhaseOne and NeutroPhase a wound care products using hypochlorous acid for cleansing, irrigation, and treating injuries.
- Jan 2026Post IPO$134M
- Aug 2025Post IPO$6M
- Mar 2024Post IPO$665K
- Sep 2022Post IPO—
#2
Seed · Emeryville, California · founded 2016$117.3Mraised▾
Developer of cell therapies focused on restoring immune tolerance for autoimmune diseases. The company’s therapeutic platform aims to provide function and balance to the immune system. It focuses on therapies that address symptoms and restore long-term immune tolerance in patients with autoimmunity. The company’s approach is based on research into regulatory T cells and their role in preventing autoimmune diseases. The company’s leadership team includes experts in biologics, cell therapy, and pharmaceutical development.
- Mar 2025Grant (prize money)$37.3M
- Mar 2025Seed$80M
#3
Series B · Emeryville, California · founded 2011 · 9 employees$11.8Mraised▾
Newomics commercializes innovative and integrative platforms and solutions for personalized healthcare. Their proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS) and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Their core technologies are built upon the multi-nozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 awards. They are currently supported by the Small Business Innovation Research (SBIR) program from the National Institutes of Health (NIH).
- Aug 2025Grant (prize money)$1M
- Oct 2020Series B$7.9M
- Aug 2018Series A$3.9M
- Aug 2014Grant (prize money)$3.6M
#4
Seed · Emeryville, California · founded 2022$2.9Mraised▾
Developer of enzyme ingredients for skin microbiome rebalancing. These ingredients are designed to selectively reduce harmful bacteria while preserving beneficial bacteria, addressing skin conditions like eczema and acne. The company utilizes a proprietary metagenomics platform to discover and develop these enzymes, harnessing natural biodiversity and synthetic biology. Rigorous laboratory research and clinical testing support the efficacy of these ingredients in restoring a healthy skin microbiome and improving overall skin health. The enzymes are formulated for use in skincare products.
- Jul 2025Grant (prize money)$1.5M
- Mar 2025Seed$1.4M
#5
Public · Emeryville, California · founded 2009 · 37 employees$8.2Mraised▾
Developer of a drug delivery medical device for diabetes. It offers a lead candidate NPM-119 a GLP-1 receptor agonist which is a subdermal, exenatide drug implant to treat type 2 diabetes. It is based on NanoPortal platform technology which make extended-release therapeutic implants.
- Mar 2025Post IPO$8.2M
#6
Public · Emeryville, California · 43 employees$293.9Mraised▾
BioAge develops a bioinformatics platform for biomarkers and drug discovery. The platform is focused on applying computational biology techniques for the identification of genomic biomarkers for the discovery of new medicines using AI technology.
- Feb 2024Series D$170M
#7
Public · Emeryville, California · founded 2022$3.4Mraised▾
Developer of immunotherapies for cancer treatment. It offers CD19-redirected T-cell therapies with cancer-labeling technology for the treatment of Diffuse large B cell lymphoma, Acute lymphocytic leukemia, and solid tumors.
- Jun 2025Post IPO$3.4M
#8
Series E · Emeryville, California · founded 2006 · 42 employees$155.2Mraised▾
Biopharmaceutical firm pioneering T-cell therapies for solid tumors and malignancies. The company is dedicated to developing transformative technology platforms to access cancer-specific targets and harness the evolutionary power of T cells. They focus on creating potential treatment options for patients by cultivating a deeper understanding of each type of cancer and leveraging cutting-edge technology platforms. The firm utilizes proprietary platforms for high-throughput screening to develop cancer-specific antibodies and harness the evolutionary power of T cells. Their pipeline highlights the potential to transform cancer treatment. They welcome partners and collaborators to help develop and commercialize novel and complementary technologies to tackle the challenges with solid tumors. The company's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.
- Jun 2023Grant (prize money)$10.6M
- Mar 2022Unattributed$900K
- Jan 2020Series E$45M
- Jun 2018Series E$20M
#9
Public · Emeryville, California · founded 2015 · 231 employees$65Mraised▾
Developer of immunotherapies for cancers and infectious diseases. The company's product pipeline includes GRANITE, SLATE personalized neoantigen-based immunotherapy, and bispecific antibodies for the treatment of cancer. Also, developing vaccines for COVID-19 and HIV. The company has an AI-based EDGE platform for target identification and an immunogenic vaccine platform.
- Oct 2023Grant (prize money)$10M
- Sep 2021Post IPO$55M
- Sep 2018Post IPO—
#10
Series C · Emeryville, California · founded 2018 · 143 employees$227Mraised▾
Nutcracker Therapeutics is a developer of proprietary technology for creating mRNA therapeutics. The proprietary technology platform is used to develop the production of patient-specific mRNA-therapeutics on single-use biochips. The platform offers features such as rapid cycles and software-controlled automated process control that uses a library of indication-specific delivery vehicles
- Mar 2022Series C$167M
- May 2020Series B$60M
#11
Series A · Emeryville, California · founded 2019 · 40 employees$21Mraised▾
Developer of screening systems to address medical needs. The company develops a Hyper-Throughput Screening system (HyTS) a technology developed by the Triplebar platform that allows users to screen candidates from both biological and synthetic libraries to find the right antibody with the best profile on an accelerated discovery timeline.
- Jan 2024Conventional Debt—
- Oct 2023Series A$21M
#12
Public · Emeryville, California · founded 2013 · 147 employees$186.6Mraised▾
4d Molecular Therapeutics researchers develop gene therapy products for severe genetic diseases involving a diverse array of target tissues, including the following areas: retina, heart, liver, brain (CNS), skeletal muscle, and lung. The company uses Directed Vector Evolution, a vector discovery platform to create customized gene delivery vehicles to deliver genes to any tissue or organ in the body.
- Jun 2020Series C$75M
- Sep 2018Series B$90M
- Sep 2017Series A$3M
- Jan 2016Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.